A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence

Exclusion Criteria

• •Breast-feeding women or females of childbearing potential with the intention to become pregnant during the study
• •Post-void residual urine volume (PRV) of 150 cc or more
• •Patients who experienced acute ureteral obstruction requiring an indwelling catheter
• •Patients who experienced clinically significant pelvic organ prolapse or lower urinary tract surgery within 6 months prior to the initiation of the present study
• •Patients who underwent a urinary incontinence operation within 1 year
• •Any condition that, in the opinion of the investigator, is a contraindication for anticholinergic treatment, including severe narrow-angled glaucoma, urinary retention, gastric retention, severe myasthenia, severe hepatic insufficiency or severe ulcerative colitis
• •Significant hepatic or renal disease, defined as having greater than twice the upper limit of the reference ranges for serum concentrations of aspartate aminotransferase (AST \[SGOT\]), alanine aminotransferase (ALT \[SGPT\]), alkaline phosphatase or creatinine
• •Patients who have any of neurological disorders such as stroke, multiple sclerosis, spinal cord injury, and Parkinson's disease
• •Patients who use an indwelling catheter or practice intermittent self-catheterization
• •Recurrent UTIs defined as having been treated for symptomatic UTIs 3 times or more in the last year
• •Symptomatic acute urinary tract infection (UTI) during the run-in period
• •Patients who received any of the following prohibited concomitant drugs within 14 days prior to randomization: Treatment performed within the 14 days preceding randomization, or expected to initiate treatment during the study with:
• •* Any anticholinergics other than the trial drug
• •* Any drug treatment for overactive bladder. Estrogen treatment started more than 2 months prior to inclusion is allowed
• •Patients taking an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
• •Patients with chronic constipation or history of severe constipation
• •Treatment with any of potent CYP3A4 inhibitors, such as cyclosporine, vinblastine, macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal agents (e.g. ketoconazole, itraconazole, micronazole)
• •Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study initiation and not agreeing to use such methods during the entire study period and for at least 1 month thereafter. Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives, surgical procedures (tubal ligation or vasectomy), or continence
• •Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion